First Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND Filing

Retrieved on: 2023-01-13 21:13:11

Tags for this article:

Pancreas disorders

Medical specialties

Health

RTT

Organ systems

Food and Drug Administration

Drug safety

Chronic pancreatitis

Cystic fibrosis

Investigational New Drug

Pancreatitis

Exocrine pancreatic insufficiency

Click the tags to see associated articles and topics

First Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND Filing. View article details on HISWAI: https://www.marketwatch.com/story/first-wave-biopharma-shares-jump-21-on-fda-review-of-adrulipase-ind-filing-271673644218

Excerpt

By Denny Jacob First Wave BioPharma Inc. shares jumped 21% to 79 cents in after-hours trading Friday following news that the Food and Drug ...

Article found on: www.marketwatch.com

View Original Article